Aerami Therapeutics has announced new additions to its management team as the company prepares for the imminent initiation of the planned “uniPHied” Phase 2 trial of AER-901 (inhaled imatinib), in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
AER-901 is a drug-device combination delivered via a high-performance, handheld nebulizer that controls flow rate and provides patients with real-time feedback to help optimize lung deposition of imatinib.
Read more on the Aerami Therapeutics press release at this link